Pay in 4 interest-free payments of $6.41 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
M.SalvesenO.SteffensenB.BixoM.Gomez-RealF.et al (2019)
In a randomized, single-blind, 24-week study, participants assigned to dual therapy of 2 mg weekly of the GLP-1 receptor agonist exenatide (Bydureon, AstraZeneca) and 10 mg daily of the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) lost more weight than those taking either agent alone or those receiving dapagliflozin and metformin extended-release (Xigduo XL, AstraZeneca) or phentermine/topiramate extended-release (Qsymia, Vivus)
Some people with very sensitive skin might prefer using it every other day initially
Medication shipped and billed monthly You can pause or cancel at any time before your next shipment * Prescription products require an online evaluation with a licensed medical professional who will determine if a prescription is appropriate
Conclusion The GLP-1 RAs in people with obesity or type 2 diabetes are associated with a significant reduction in all-cause death, alongside an increased risk of pancreatic adverse eventsparticularly acute pancreatitismost pronounced during the first 6 months of treatment
US$ 24.80
US$ 28.37
US$ 24.62
US$ 29.79
US$ 25.96
US$ 26.26
